We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+11.16%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$1.09B
AUM Growth
+$89.1M
Cap. Flow
-$8.77M
Cap. Flow %
-0.8%
Top 10 Hldgs %
54.62%
Holding
69
New
7
Increased
12
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$13.3M
2
INCY icon
Incyte
INCY
+$10.7M
3
PFE icon
Pfizer
PFE
+$10.1M
4
BMY icon
Bristol-Myers Squibb
BMY
+$9.98M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$5.12M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$19.4M
2
PRGO icon
Perrigo
PRGO
+$14.9M
3
AGN
Allergan Inc
AGN
+$9.3M
4
IBB icon
iShares Biotechnology ETF
IBB
+$8.72M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$7.6M

Sector Composition

Rank Sector Weight
1 Healthcare 88.61%
2 Financials 1.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FRX
26
DELISTED
FOREST LABORATORIES INC
FRX
$10.9M 1%
109,875
-36,625
-25% -$3.42M
HRTX icon
27
Heron Therapeutics
HRTX
$94.1M
$10.8M 0.99%
873,940
+177,343
+25% +$2.12M
ALR
28
DELISTED
Alere Inc
ALR
$10.7M 0.98%
286,540
– –
SGNT
29
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$10.5M 0.96%
404,731
– –
IPXL
30
DELISTED
Impax Laboratories, Inc.
IPXL
$10.3M 0.95%
344,683
– –
CTRX
31
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$10.2M 0.94%
231,000
– –
PFE icon
32
Pfizer
PFE
$142B
$9.94M 0.91%
+353,045
New +$10.1M
BMY icon
33
Bristol-Myers Squibb
BMY
$132B
$9.83M 0.9%
+202,600
New +$9.98M
MOH icon
34
Molina Healthcare
MOH
$10.2B
$9.49M 0.87%
212,541
+107,541
+102% +$4.36M
PRGO icon
35
Perrigo
PRGO
$1.43B
$9.18M 0.84%
62,952
-104,922
-63% -$14.9M
ENDP
36
DELISTED
Endo International plc
ENDP
$8.84M 0.81%
126,215
– –
INFI
37
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$8.67M 0.8%
680,746
+330,847
+95% +$3.45M
VSTM icon
38
Verastem
VSTM
$536M
$8.32M 0.76%
76,569
– –
RVTY icon
39
Revvity
RVTY
$12.7B
$7.75M 0.71%
165,495
– –
ACOR
40
DELISTED
Acorda Therapeutics
ACOR
$7.61M 0.7%
1,881
+940
+100% +$3.83M
IDXX icon
41
Idexx Laboratories
IDXX
$44.1B
$7.51M 0.69%
112,530
– –
TMO icon
42
Thermo Fisher Scientific
TMO
$214B
$7.04M 0.65%
59,660
– –
UNH icon
43
UnitedHealth
UNH
$383B
$6.8M 0.62%
83,186
+750
+0.9% +$59K
ARAY icon
44
Accuray
ARAY
$34M
$6.44M 0.59%
731,943
– –
BDSI
45
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$6.05M 0.56%
501,553
-181,707
-27% -$1.72M
IPCI
46
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$5.35M 0.49%
140,400
– –
CNC icon
47
Centene
CNC
$30.1B
$4.54M 0.42%
240,000
– –
MNTA
48
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.27M 0.39%
+353,475
New +$4.18M
MACK
49
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$4.14M 0.38%
72,166
-24,055
-25% -$1.22M
ALNY icon
50
Alnylam Pharmaceuticals
ALNY
$27.5B
$3.89M 0.36%
61,595
– –
1
2
3

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, Tekla Capital Management held 69 positions worth $1.09B, up 8.9% from $1B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Tekla Capital Management's Q2 2014 filing shows 7 new, 12 increased, 10 reduced and 5 closed positions. Its largest new stake was Jazz Pharmaceuticals: 95,957 shares worth $14.1M. The largest sale was Puma Biotechnology, an estimated $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 87% a quarter earlier, followed by Financials.

  • Tekla Capital Management's largest Q2 2014 buy was Jazz Pharmaceuticals: 95,957 shares worth $14.1M.
  • Tekla Capital Management added most to Incyte in Q2 2014, an estimated $10.7M increase.
  • Tekla Capital Management's biggest Q2 2014 reduction was Perrigo, cutting an estimated $14.9M.
  • Tekla Capital Management fully exited Puma Biotechnology in Q2 2014, selling an estimated $19.4M.
  • Tekla Capital Management's ten largest holdings make up 55% of its $1.09B portfolio in Q2 2014.
  • Tekla Capital Management opened 7 new positions and closed 5 in Q2 2014.
  • Tekla Capital Management's portfolio value rose 8.9% quarter-over-quarter to $1.09B.

Based on Tekla Capital Management's 13F filing for Q2 2014, filed 5 Aug 2014.